The Health Impact Fund (HIF) is intended to provide competitive returns to firms that develop drugs and vaccines to treat the diseases mostly prevalent in low- and middle-income countries. A smaller version – the “mini-HIF” – could effectively demonstrate viability of this approach. The benefits of supporting the mini-HIF are:
The most effective mini-HIF would be funded in the range of $60m – $200m, ideally with funding from several sources including foundations and governments.
The mini-HIF would be a competition for pharmaceutical manufacturers and PDPs to achieve health impact through an innovative drug, vaccine, delivery mechanism or formulation used mainly in low- and middle-income countries (a “project”). Firms and PDPs would be invited to bid through a Request for Proposals; successful proposals would become eligible for rewards based on health impact achieved through the initiative. The available reward pool would be divided among the accepted projects in proportion to the health impact achieved by each.
The mini-HIF would create incentives for investment into improving the health of poor people. For further details, please get in touch with us at firstname.lastname@example.org
This book presents an in-depth overview of the Health Impact Fund’s proposed MiniHIF initiative. The mini-HIF focuses on demonstrating the feasibility of rewarding new drugs based on assessed health impact.